Secukinumab Improves Physical Function in Subjects With Plaque Psoriasis and Psoriatic Arthritis: Results from Two Randomized, Phase 3 Trials.

塞库金单抗 医学 银屑病性关节炎 依那西普 安慰剂 银屑病 银屑病面积及严重程度指数 相伴的 随机对照试验 内科学 皮肤病科 胃肠病学 肿瘤坏死因子α 病理 替代医学
作者
Alice B. Gottlieb,Richard Langley,Sandra Philipp,Bárður Sigurgeirsson,Andrew Blauvelt,Ruvie Martin,C. Papavassilis,Shephard Mpofu
出处
期刊:PubMed 卷期号:14 (8): 821-33 被引量:49
链接
标识
摘要

Interleukin (IL)-17A is a key cytokine in the pathogenesis of psoriatic disease of the skin and joints. In phase 3 trials, secukinumab, a fully human anti-IL-17A monoclonal antibody, demonstrated robust efficacy in psoriasis, with rapid onset, high response rates, and durable response.To evaluate the efficacy of secukinumab in subjects with psoriasis and concomitant psoriatic arthritis (PsA) with respect to psoriasis symptoms and physical function, we conducted pre-specified subanalyses of the phase 3 FIXTURE and ERASURE trials.The 52-week FIXTURE and ERASURE trials randomized subjects with moderate-to-severe plaque psoriasis to subcutaneous secukinumab 300 or 150 mg (Baseline, weeks 1, 2, 3, every 4 weeks from week 4 until week 48), etanercept 50 mg (twice weekly through week 12, once weekly thereafter through week 51; FIXTURE only), or placebo. In this analysis, changes in Health Assessment Questionnaire-Disability Index (HAQ-DI) and PASI 75 responses were assessed in subpopulations with concomitant PsA (n=196, FIXTURE; n=171, ERASURE).Physical functioning (mean change from Baseline in HAQ-DI) was greater with secukinumab 300 mg vs. placebo at week 12 in both trials (FIXTURE, -0.41 vs. 0.02/P=0.0001; ERASURE, -0.35 vs. -0.08/P=0.0003); corresponding values were -0.29 for etanercept and -0.19 for secukinumab 150 mg in FIXTURE and -0.18 for secukinumab 150 mg in ERASURE. Greater responses were seen in subjects with greater Baseline disability (HAQ-DI ≥05). Week 12 PASI 75 responses were higher with secukinumab 300 mg/150 mg vs. placebo in FIXTURE (72%/59% vs. 2%) and ERASURE (68%/70% vs. 4%; all P<0.0001) and with secukinumab 300 mg vs. etanercept (72% vs 39%; P=0.0084).Secukinumab 300 mg produced significant improvement in psoriasis and physical functioning in subjects with concomitant PsA. ClinicalTrials.gov numbers: NCT01358578 (FIXTURE); NCT01365455 (ERASURE)

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
大幅提高文件上传限制,最高150M (2024-4-1)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
柳一发布了新的文献求助10
刚刚
yin完成签到,获得积分10
1秒前
1秒前
1秒前
研友_LwlAgn发布了新的文献求助10
1秒前
诚心采白发布了新的文献求助10
2秒前
MIAAAAAAO完成签到,获得积分10
3秒前
5秒前
Ava应助psj采纳,获得10
5秒前
yuna完成签到 ,获得积分10
5秒前
周胖胖发布了新的文献求助10
6秒前
美好斓发布了新的文献求助10
6秒前
华仔应助yangshujuan采纳,获得10
6秒前
wanci应助研友_LwlAgn采纳,获得10
7秒前
安青兰完成签到 ,获得积分10
7秒前
8秒前
共享精神应助研友_V8Qmr8采纳,获得10
8秒前
9秒前
10秒前
xixi应助阿楠采纳,获得10
10秒前
。.。发布了新的文献求助10
10秒前
嘻嘻嘻嘻嘻完成签到,获得积分20
11秒前
12秒前
薰硝壤应助小毛毛采纳,获得10
12秒前
科研通AI2S应助多多采纳,获得10
13秒前
结实灭男发布了新的文献求助10
14秒前
sandy完成签到,获得积分10
14秒前
cheng发布了新的文献求助10
15秒前
吴所畏惧发布了新的文献求助10
15秒前
ms完成签到,获得积分10
16秒前
123应助老侯采纳,获得30
17秒前
高高白曼舞完成签到,获得积分10
17秒前
17秒前
爱笑的莺完成签到,获得积分10
18秒前
二零三完成签到,获得积分10
18秒前
19秒前
19秒前
19秒前
19秒前
在水一方应助火羽白日生采纳,获得10
19秒前
高分求助中
Sustainability in Tides Chemistry 2000
Microlepidoptera Palaearctica, Volumes 1 and 3 - 13 (12-Volume Set) [German] 1122
Дружба 友好报 (1957-1958) 1000
The Data Economy: Tools and Applications 1000
A Dissection Guide & Atlas to the Rabbit 600
中国心血管健康与疾病报告2023(要完整的报告) 500
Ожившие листья и блуждающие цветы. Практическое руководство по содержанию богомолов [Alive leaves and wandering flowers. A practical guide for keeping praying mantises] 500
热门求助领域 (近24小时)
化学 医学 生物 材料科学 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 基因 遗传学 催化作用 物理化学 免疫学 量子力学 细胞生物学
热门帖子
关注 科研通微信公众号,转发送积分 3102053
求助须知:如何正确求助?哪些是违规求助? 2753346
关于积分的说明 7623434
捐赠科研通 2406027
什么是DOI,文献DOI怎么找? 1276521
科研通“疑难数据库(出版商)”最低求助积分说明 616877
版权声明 599103